Opin vísindi

Fletta eftir höfundi "Andrade, Raul J"

Fletta eftir höfundi "Andrade, Raul J"

Röðun: Raða: Niðurstöður:

  • Daly, Ann K.; Björnsson, Einar Stefán; Lucena, M. Isabel; Andrade, Raul J.; Aithal, Guruprasad P. (2023-05)
  • Fontana, Robert J; Björnsson, Einar Stefán; Reddy, Rajender; Andrade, Raul J (2023-07)
    Idiosyncratic drug-induced liver injury (DILI) is an infrequent but important cause of liver disease. Newly identified causes of DILI include the COVID vaccines, turmeric, green tea extract, and immune checkpoint inhibitors. DILI is largely a clinical ...
  • Nicoletti, Paola; Devarbhavi, Harshad; Goel, Ashish; Venkatesan, Radha; Eapen, Chundamannil E.; Grove, Jane I.; Zafer, Samreen; Björnsson, Einar Stefán; Lucena, M. Isabel; Andrade, Raul J.; Pirmohamed, Munir; Wadelius, Mia; Larrey, Dominique; Maitland-van der Zee, Anke Hilse; Ibanez, Luisa; Watkins, Paul B.; Daly, Ann K.; Aithal, Guruprasad P. (2021-04)
    Drug-induced liver injury (DILI) is a complication of treatment with antituberculosis (TB) drugs, especially in isoniazid (INH)-containing regimens. To investigate genetic risk factors, we performed a genomewide association study (GWAS) involving anti-TB ...
  • Björnsson, Einar Stefán; Stephens, Camilla; Atallah, Edmond; Robles-Diaz, Mercedes; Alvarez-Alvarez, Ismael; Gerbes, Alexander; Weber, Sabine; Stirnimann, Guido; Kullak-Ublick, Gerd; Cortez-Pinto, Helena; Grove, Jane I.; Lucena, M. Isabel; Andrade, Raul J.; Aithal, Guruprasad P. (2023-01-01)
    Background & Aims: No multi-national prospective study of drug-induced liver injury (DILI) has originated in Europe. The design of a prospective European DILI registry, clinical features and short-term outcomes of the cases and controls is reported. ...
  • Sanabria-Cabrera, Judith; Tabbai, Sara; Niu, Hao; Alvarez-Alvarez, Ismael; Licata, Anna; Björnsson, Einar Stefán; Andrade, Raul J.; Lucena, M. Isabel (2022-05-17)
    Introduction: Idiosyncratic drug-induced liver injury (DILI) is a rare adverse reaction to drugs and other xenobiotics. DILI has different grades of severity and may lead to acute liver failure (ALF), for which there is no effective therapy. N-acetylcysteine ...
  • Niu, Hao; Sanabria-Cabrera, Judith; Alvarez-Alvarez, Ismael; Robles-Diaz, Mercedes; Stankevičiūtė, Simona; Aithal, Guruprasad P.; Björnsson, Einar Stefán; Andrade, Raul J.; Lucena, M. Isabel (2021-02)
    Conducting randomised clinical trials (RCTs) in idiosyncratic drug-induced liver injury (DILI) is challenging. This systematic review aims to summarise the design and findings of RCTs in the prevention and management of idiosyncratic DILI. A systematic ...
  • Hayashi, Paul H; Lucena, M Isabel; Fontana, Robert J; Björnsson, Einar Stefán; Aithal, Guruprasad P; Barnhart, Huiman; Gonzalez-Jimenez, Andres; Yang, Qinghong; Gu, Jiezhun; Andrade, Raul J; Hoofnagle, Jay H (2022-07)
    BACKGROUND AND AIMS: Roussel Uclaf Causality Assessment Method (RUCAM) for DILI has been hindered by subjectivity and poor reliability. We sought to improve the RUCAM using data from the Drug-Induced Liver Injury Network (DILIN) and the Spanish DILI ...
  • Björnsson, Einar S.; Medina-Caliz, Inmaculada; Andrade, Raul J.; Lucena, M. Isabel (2022-05-21)
    Nitrofurantoin, minocycline, methyldopa and infliximab, have been found to induce autoimmune-like hepatitis (DI-AILH). Evidence for other drugs and herbal and dietary supplements (HDS) is unclear. The aims of the study were to establish criteria to ...
  • Ravindra, Kodihalli C; Vaidya, Vishal S; Wang, Zhenyu; Federspiel, Joel D; Virgen-Slane, Richard; Everley, Robert A; Grove, Jane I; Stephens, Camilla; Ocana, Mireia F; Robles-Díaz, Mercedes; Isabel Lucena, M; Andrade, Raul J; Atallah, Edmond; Gerbes, Alexander L; Weber, Sabine; Cortez-Pinto, Helena; Fowell, Andrew J; Hussaini, Hyder; Björnsson, Einar Stefán; Patel, Janisha; Stirnimann, Guido; Verma, Sumita; Elsharkawy, Ahmed M; Griffiths, William J H; Hyde, Craig; Dear, James W; Aithal, Guruprasad P; Ramaiah, Shashi K (2023-03-03)
    Diagnosis of drug-induced liver injury (DILI) and its distinction from other liver diseases are significant challenges in drug development and clinical practice. Here, we identify, confirm, and replicate the biomarker performance characteristics of ...